Hot flashes are common symptoms of complications associated with menopause and may occur during daytime or at night. The severity of hot flashes varies from women to women as it depends on many physiochemical factors. The intensity may be mild, mediocre and troublesome, or debilitating and severe. One of the standard treatments for menopausal hot flashes is the Hormone Replacement Therapy (HRT). Some other therapies include intake of anti-depressants and vitamin E along with numerous complementary therapies. In the U.S. and other developed nations, 70% of menopausal women commonly suffer from hot flashes that may last for many years.
Browse Full Report: http://www.transparencymarketresearch.com/menopausal-hot-flashes.html
The worldwide rise in the menopausal vasomotor symptoms, growing health awareness among women, and approval of new treatments are some of the factors expected to drive the global menopausal hot flashes market in the years to come. The increasing number of medical centers for treating menopausal hot flashes is expected to boost the global menopausal hot flashes market in the next few years.
Lately, Premier Women’s Health, a gynecological practice, announced its new treatment for menopausal hot flashes in the U.S. Premier Women’s Health is dedicated to offering comprehensive care through corrective and preventive therapies. With its three centers across South Alabama, Premier Women’s Health offers various therapies and treatments. Along with some traditional methods, Premier Women’s Health introduced some specialized methods to treat menopausal hot flashes.
North America Leads Global Menopausal Hot Flashes Market
The global menopausal hot flashes market stood at US$3.77 bn in 2014 and is predicted to reach US$5.28 bn by 2023, progressing at a 3.70% CAGR for the period between 2015 and 2023. The global menopausal hot flashes market is segmented on the basis of therapy and geography.
Based on geography, the global menopausal hot flashes market is divided into Europe, Asia Pacific, North America, Latin America, the Middle East and Africa, and Rest of the World. Currently, North America dominates the global menopausal hot flashes market and is expected to maintain its dominant position throughout the forecast period. The rising disposable income, large population pool, increasing women’s health awareness, and rapid urbanization are some of the factors expected to propel the Asia Pacific menopausal hot flashes market in the years to come.
Brazil to Create Growth Opportunities in Global Menopausal Hot Flashes Market
The untapped market in the Rest of the World region will boost the global menopausal hot flashes market by 2023. As per a report published in 2014, Brazil registered the maximum number of women approaching menopause. In 2014, around 30 million women in Brazil who approached menopause, were aged between 35 and 65 years. This created growth opportunities for the leading players in the global menopausal hot flashes market.
Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/menopausal-hot-flashes.htm
The global menopausal hot flashes market is highly competitive and fragmented due to the presence of many small scale and large scale companies. The top 10 leading manufacturers, in 2014, accounted for 44.5% of the global menopausal hot flashes market. Some of the prominent players in the global menopausal hot flashes market are Allergan plc, Hisamitsu Pharmaceutical Co., Inc., Novartis International AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Merck & Co., Inc., and Novo Nordisk Corporation.
No comments:
Post a Comment